The U.S. National Institutes of Health has started a mid-stage study to determine the risk of allergic reactions to COVID-19 vaccines made by Moderna and Pfizer Incorporated.
Several allergic reaction incidents, including serious episodes, known as anaphylaxis, have been reported in the U.S. after vaccinations of Pfizer/BioNTech and Moderna shots.
In January, the U.S. Centers for Disease Control and Prevention (CDC) said allergic reactions are occurring at a rate of 11.1 per one million vaccinations.
The study, funded by the National Institute of Allergy and Infectious Diseases, will enroll 3,400 adults from ages 18 to 69, with about 60% participants having a history of severe allergic reactions to food, insect stings or immunotherapy.
The goal of the trial is to access the proportion of participants who have a systemic allergic reaction within 90 minutes after injection.
The agency expects to report data this summer.